Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient.
Wen LiRuixin LiuXuelin LiBei TaoNan ZhaiXiaolin WangQi LiYifei ZhangWeiqiong GuWeiqing WangGuang NingPublished in: Journal of diabetes (2019)
Type 2 diabetes patients with OW/OB exhibited greater improvement in glycemic control and additional metabolic benefits after saxagliptin treatment. Saxagliptin significantly increased the BA pool, and DCA and GDCA were associated with metabolic improvements in OW/OB T2D patients.
Keyphrases
- type diabetes
- glycemic control
- weight loss
- blood glucose
- end stage renal disease
- insulin resistance
- ejection fraction
- cardiovascular disease
- chronic kidney disease
- bariatric surgery
- physical activity
- metabolic syndrome
- adipose tissue
- prognostic factors
- peritoneal dialysis
- emergency department
- body mass index
- skeletal muscle
- obese patients